U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Metastatic Malignant Neoplasm in the Prostate Gland

MedGen UID:
87566
•Concept ID:
C0347001
•
Neoplastic Process
Synonyms: Cancer metastatic to prostate; Metastases to Prostate; Metastases to the Prostate; Metastasis to prostate; Metastasis to Prostate; Metastasis to the Prostate; Metastatic malignant neoplasm of prostate; Metastatic malignant neoplasm to prostate; Metastatic Malignant Neoplasm to the Prostate Gland; Metastatic Neoplasm to the Prostate; Metastatic tumor to prostate; Metastatic Tumor to the Prostate; Secondary malignant neoplasm of prostate
SNOMED CT: Metastatic tumor to prostate (94503003); Metastasis to prostate (94503003); Secondary malignant neoplasm of prostate (94503003); Metastatic malignant neoplasm to prostate (94503003); Cancer metastatic to prostate (94503003); Metastatic malignant neoplasm of prostate (94503003)

Definition

The spread of a malignant neoplasm to the prostate gland from an adjacent or distant anatomic site. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVMetastatic Malignant Neoplasm in the Prostate Gland

Professional guidelines

PubMed

Optimal Management of Prostate Cancer Based on its Natural Clinical History.
Facchini G, Perri F, Misso G, D'Aniello C, Scarpati GDV, Rossetti S, Pepa CD, Pisconti S, Unteregger G, Cossu A, Caraglia M, Berretta M, Cavaliere C
Curr Cancer Drug Targets 2018;18(5):457-467. doi: 10.2174/1568009617666170209093101. PMID: 28183253
Blockade of testicular and adrenal androgens in prostate cancer treatment.
Labrie F
Nat Rev Urol 2011 Feb;8(2):73-85. Epub 2011 Jan 18 doi: 10.1038/nrurol.2010.231. PMID: 21243019
External-beam radiotherapy in the management of carcinoma of the prostate.
Zlotecki RA
Cancer Control 2001 Nov-Dec;8(6):503-10. doi: 10.1177/107327480100800605. PMID: 11807420

Recent clinical studies

Etiology

Aberrant expression of GATA3 in metastatic adenocarcinoma of the prostate: an important pitfall.
Lobo J, Tenace NP, Cañete-Portillo S, Carneiro I, Henrique R, Lucianò R, Harik LR, Magi-Galluzzi C
Histopathology 2024 Feb;84(3):507-514. Epub 2023 Nov 15 doi: 10.1111/his.15094. PMID: 37965687
An Intrapatient Dosimetry Comparison of (177)Lu-rhPSMA-10.1 and (177)Lu-PSMA-I&T in Patients with Metastatic Castration-Resistant Prostate Cancer.
Rinscheid A, Gäble A, Wienand G, Pfob C, Dierks A, Kircher M, Trepel M, Weckermann D, Lapa C, Bundschuh RA
J Nucl Med 2023 Dec 1;64(12):1918-1924. doi: 10.2967/jnumed.123.265970. PMID: 37770108
More advantages in detecting bone and soft tissue metastases from prostate cancer using (18)F-PSMA PET/CT.
Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE
Hell J Nucl Med 2019 Jan-Apr;22(1):6-9. Epub 2019 Mar 7 doi: 10.1967/s002449910952. PMID: 30843003
Histopathology of Prostate Cancer.
Humphrey PA
Cold Spring Harb Perspect Med 2017 Oct 3;7(10) doi: 10.1101/cshperspect.a030411. PMID: 28389514Free PMC Article
Distribution of metastatic sites in patients with prostate cancer: A population-based analysis.
Gandaglia G, Abdollah F, Schiffmann J, Trudeau V, Shariat SF, Kim SP, Perrotte P, Montorsi F, Briganti A, Trinh QD, Karakiewicz PI, Sun M
Prostate 2014 Feb;74(2):210-6. Epub 2013 Oct 16 doi: 10.1002/pros.22742. PMID: 24132735

Diagnosis

More advantages in detecting bone and soft tissue metastases from prostate cancer using (18)F-PSMA PET/CT.
Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE
Hell J Nucl Med 2019 Jan-Apr;22(1):6-9. Epub 2019 Mar 7 doi: 10.1967/s002449910952. PMID: 30843003
Mucinous and secondary tumors of the prostate.
Osunkoya AO
Mod Pathol 2018 Jan;31(S1):S80-S95. doi: 10.1038/modpathol.2017.132. PMID: 29297488
Histopathology of Prostate Cancer.
Humphrey PA
Cold Spring Harb Perspect Med 2017 Oct 3;7(10) doi: 10.1101/cshperspect.a030411. PMID: 28389514Free PMC Article
Rediscovering Secondary Tumors of the Prostate in the Molecular Era.
Fusco N, Sciarra A, Guerini-Rocco E, Marchiò C, Vignani F, Colombo P, Ferrero S
Adv Anat Pathol 2016 May;23(3):170-9. doi: 10.1097/PAP.0000000000000115. PMID: 27058245
Distribution of metastatic sites in patients with prostate cancer: A population-based analysis.
Gandaglia G, Abdollah F, Schiffmann J, Trudeau V, Shariat SF, Kim SP, Perrotte P, Montorsi F, Briganti A, Trinh QD, Karakiewicz PI, Sun M
Prostate 2014 Feb;74(2):210-6. Epub 2013 Oct 16 doi: 10.1002/pros.22742. PMID: 24132735

Therapy

An Intrapatient Dosimetry Comparison of (177)Lu-rhPSMA-10.1 and (177)Lu-PSMA-I&T in Patients with Metastatic Castration-Resistant Prostate Cancer.
Rinscheid A, Gäble A, Wienand G, Pfob C, Dierks A, Kircher M, Trepel M, Weckermann D, Lapa C, Bundschuh RA
J Nucl Med 2023 Dec 1;64(12):1918-1924. doi: 10.2967/jnumed.123.265970. PMID: 37770108
Preclinical Models of Neuroendocrine Prostate Cancer.
Cacciatore A, Albino D, Catapano CV, Carbone GM
Curr Protoc 2023 May;3(5):e742. doi: 10.1002/cpz1.742. PMID: 37166213
Emerging treatments for recurrent prostate cancer.
Hanna C, Jones RJ
Future Oncol 2015;11(21):2873-80. Epub 2015 Oct 5 doi: 10.2217/fon.15.228. PMID: 26436556
The prostate-specific antigen test.
Roobol MJ
Expert Opin Med Diagn 2013 Sep;7(5):423-6. Epub 2013 Jul 23 doi: 10.1517/17530059.2013.821980. PMID: 23875974
Blockade of testicular and adrenal androgens in prostate cancer treatment.
Labrie F
Nat Rev Urol 2011 Feb;8(2):73-85. Epub 2011 Jan 18 doi: 10.1038/nrurol.2010.231. PMID: 21243019

Prognosis

Preclinical Models of Neuroendocrine Prostate Cancer.
Cacciatore A, Albino D, Catapano CV, Carbone GM
Curr Protoc 2023 May;3(5):e742. doi: 10.1002/cpz1.742. PMID: 37166213
More advantages in detecting bone and soft tissue metastases from prostate cancer using (18)F-PSMA PET/CT.
Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE
Hell J Nucl Med 2019 Jan-Apr;22(1):6-9. Epub 2019 Mar 7 doi: 10.1967/s002449910952. PMID: 30843003
Mucinous and secondary tumors of the prostate.
Osunkoya AO
Mod Pathol 2018 Jan;31(S1):S80-S95. doi: 10.1038/modpathol.2017.132. PMID: 29297488
Histopathology of Prostate Cancer.
Humphrey PA
Cold Spring Harb Perspect Med 2017 Oct 3;7(10) doi: 10.1101/cshperspect.a030411. PMID: 28389514Free PMC Article
Rediscovering Secondary Tumors of the Prostate in the Molecular Era.
Fusco N, Sciarra A, Guerini-Rocco E, Marchiò C, Vignani F, Colombo P, Ferrero S
Adv Anat Pathol 2016 May;23(3):170-9. doi: 10.1097/PAP.0000000000000115. PMID: 27058245

Clinical prediction guides

Characterization of HOXB13 expression patterns in localized and metastatic castration-resistant prostate cancer.
Patel RA, Sayar E, Coleman I, Roudier MP, Hanratty B, Low JY, Jaiswal N, Ajkunic A, Dumpit R, Ercan C, Salama N, O'Brien VP, Isaacs WB, Epstein JI, De Marzo AM, Trock BJ, Luo J, Brennen WN, Tretiakova M, Vakar-Lopez F, True LD, Goodrich DW, Corey E, Morrissey C, Nelson PS, Hurley PJ, Gulati R, Haffner MC
J Pathol 2024 Jan;262(1):105-120. Epub 2023 Oct 18 doi: 10.1002/path.6216. PMID: 37850574Free PMC Article
The ADAM9/WISP-1 axis cooperates with osteoblasts to stimulate primary prostate tumor growth and metastasis.
Chang AC, Lin LW, Chen YC, Chen PC, Liu SC, Tai HC, Wu HC, Sung SY, Lin TH, Tang CH
Int J Biol Sci 2023;19(3):760-771. Epub 2023 Jan 1 doi: 10.7150/ijbs.77495. PMID: 36778124Free PMC Article
More advantages in detecting bone and soft tissue metastases from prostate cancer using (18)F-PSMA PET/CT.
Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE
Hell J Nucl Med 2019 Jan-Apr;22(1):6-9. Epub 2019 Mar 7 doi: 10.1967/s002449910952. PMID: 30843003
Connexins, important players in the dissemination of prostate cancer cells.
Boucher J, Monvoisin A, Vix J, Mesnil M, Thuringer D, Debiais F, Cronier L
Biochim Biophys Acta Biomembr 2018 Jan;1860(1):202-215. Epub 2017 Jul 8 doi: 10.1016/j.bbamem.2017.06.020. PMID: 28693897
Is There Use for FDG-PET in Prostate Cancer?
Jadvar H
Semin Nucl Med 2016 Nov;46(6):502-506. Epub 2016 Sep 3 doi: 10.1053/j.semnuclmed.2016.07.004. PMID: 27825430Free PMC Article

Recent systematic reviews

Overall Survival After Systemic Treatment in High-volume Versus Low-volume Metastatic Hormone-sensitive Prostate Cancer: Systematic Review and Network Meta-analysis.
Wenzel M, Würnschimmel C, Nocera L, Collà Ruvolo C, Tian Z, Shariat SF, Saad F, Briganti A, Tilki D, Graefen M, Kluth LA, Roos FC, Mandel P, Chun FKH, Karakiewicz PI
Eur Urol Focus 2022 Mar;8(2):399-408. Epub 2021 Apr 11 doi: 10.1016/j.euf.2021.04.003. PMID: 33853754
Malignant melanoma of the prostate gland: A systematic review.
Caputo A, Addesso M, Zeppa P, D'Antonio A
Pathol Res Pract 2021 Oct;226:153594. Epub 2021 Aug 24 doi: 10.1016/j.prp.2021.153594. PMID: 34481214

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...